Bulk Inquiry
Deltarasin trihydrochloride
- Parent CAS: 1440898-61-2
- Optical Purity: Optically pure
- Soluble in water and DMSO
- MF: C40H37N5O.3HCl
- MW: 713.14
Description
Deltarasin trihydrochloride is a small-molecule inhibitor of the KRAS–PDEδ interaction with a reported cellular Kd value of 41 nM for binding to PDEδ. It disrupts oncogenic KRAS localization to endomembranes and suppresses MAPK signaling and proliferation in KRAS-dependent pancreatic ductal adenocarcinoma models.
PDEδ-mediated trafficking supports membrane localization and signaling of prenylated KRAS, a key oncogenic driver in pancreatic and other cancers. Deltarasin is useful for investigating KRAS spatial regulation and RAS/MAPK pathway dependency.
Key Features
- KRAS–PDEδ interaction inhibitor
- Cellular Kd: 41 nM for PDEδ binding
- Disrupts KRAS endomembrane localization
- Suppresses KRAS-dependent MAPK signaling
Applications
- KRAS localization studies
- RAS/MAPK signaling assays
- Pancreatic cancer model research
- Protein–protein interaction inhibitor profiling
More Information
| Parent CAS No. | 1440898-61-2 |
|---|---|
| Chemical Name | (S)-1-benzyl-2-(4-(2-(2-phenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethylphenyl-1H-benzo[d]imidazol-1-yl)-2-(piperidin-4-yl)ethoxy)phenyl)-1H-benzo[d]imidazole trihydrochloride |
| SMILES | C1C=C2N=C(C3C=CC(OC[C@H](C4CCNCC4)N4C5C=CC=CC=5N=C4C4C=CC=CC=4)=CC=3)N(CC3C=CC=CC=3)C2=CC=1.Cl.Cl.Cl |&1:11,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C40H37N5O.3ClH/c1-3-11-29(12-4-1)27-44-36-17-9-7-15-34(36)42-39(44)32-19-21-33(22-20-32)46-28-38(30-23-25-41-26-24-30)45-37-18-10-8-16-35(37)43-40(45)31-13-5-2-6-14-31;;;/h1-22,30,38,41H,23-28H2;3*1H/t38-;;;/m1.../s1 |
| InChiKey | NCIOVAYUMQEQEU-VKZSUDIWSA-N |
| CID | 91826089 |
| Short Description | KRAS-PDEδ inhibitor |
References
- G. Zimmermann et al.Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013, 497, 638-642.
- B. Frett et al. Targeting the K-Ras/PDEδ Protein–Protein Interaction: The Solution for Ras-Driven Cancers or Just Another Therapeutic Mirage? ChemMedChem 2013, 8, 1620-1622.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1578 | NSC 23766 |
From $121.00 |
| 1639 | YM155 |
From $104.50 |
| 1825 | Erastin |
From $99.00 |
| 1828 | BH3I 1 |
From $137.50 |
| 1985 | Xevinapant |
From $159.50 |
| 2007 | HA 14-1 |
From $82.50 |
| 2017 | ML 210 |
From $126.50 |
| 2141 | ABT 199 |
From $77.00 |
| 2165 | S 12 |
From $115.50 |
| 2176 | LCS-1 |
From $93.50 |
| 2184 | CID 1067700 |
From $137.50 |
| 2185 | BAM 7 |
From $99.00 |
| 2293 | Ferrostatin 1 |
From $93.50 |
| 2300 | Dordaviprone |
From $132.00 |
| 2302 | Kobe 0065 |
From $77.00 |
| 2351 | EHop 016 |
From $93.50 |
| 2396 | RBC 8 |
From $115.50 |
| 2397 | BQU 57 |
From $137.50 |
| 2611 | APS-2-79 |
From $99.00 |
| 3714 | BCL-201 dihydrochloride |
From Inquiry |
| 3814 | AZD4320 |
From Inquiry |
| 3821 | ABT-263 |
From $88.00 |
